Stock Screener
Stock Research
Market Indexes
Precious Metals
Energy
Commodities
Interest Rates
Economy
Global Metrics

BridgeBio Pharma Market Cap 2018-2024 | BBIO

BridgeBio Pharma market cap history and chart from 2018 to 2024. Market capitalization (or market value) is the most commonly used method of measuring the size of a publicly traded company and is calculated by multiplying the current stock price by the number of shares outstanding. BridgeBio Pharma market cap as of December 27, 2024 is $5.37B.
  
Sector Industry Market Cap Revenue
Medical Medical - Generic Drugs $5.365B $0.009B
BridgeBio Pharma Inc. discovers, develops and innovates drugs for genetic diseases. The Company's product platform consists of Mendelian, Oncology and Gene therapy. Its product pipeline includes BBP-265, BBP-831, BBP-631 and BBP-454 which are in clinical stage. BridgeBio Pharma Inc. is based in CA, United States.
Stock Name Country Market Cap PE Ratio
Teva Pharmaceutical Industries (TEVA) Israel $25.626B 8.41
Dr Reddy's Laboratories (RDY) India $12.997B 24.87
Bausch Health Cos (BHC) Canada $2.752B 2.03
Supernus Pharmaceuticals (SUPN) United States $2.003B 27.28
Amphastar Pharmaceuticals (AMPH) United States $1.835B 11.03
Personalis (PSNL) United States $0.442B 0.00
Taysha Gene Therapies (TSHA) United States $0.381B 26.57
Assembly Biosciences (ASMB) United States $0.098B 0.00
Sol-Gel Technologies (SLGL) Israel $0.034B 0.00
Evoke Pharma (EVOK) United States $0.007B 0.00
Teligent (TLGT) United States $0.000B 0.00